Acta Neuropharmacologica››2013,Vol. 3››Issue (1): 23-27.
Previous ArticlesNext Articles
WEN Rui-ting1ZHANG Han-ting2LIANG Jian-hui3
Online:
2013-02-26Published:
2014-06-27Contact:
梁建辉,男,博士,研究员,博士生导师;研究方向:神经精神药理学;Tel:+86-010-82802452,Fax:+86-010-62032624,E-mail:liangjh@bjmu.edu.cnAbout author:
文睿婷,女,博士,主管药师;研究方向:神经精神药理学,临床药学Supported by:
国家重点基础研究发展计划(973 计划)(No.2009CB522003);国家自然科学基金(No.30870894);“十二五”国家科技支撑计划资助项目(No.2011BAK04B08);公安部重点研究计划(No.2009ZDYJHLJT003)
WEN Rui-ting ZHANG Han-ting LIANG Jian-hui.Phosphodiesterase-4 (PDE4):the Potential Therapeutic Target for Alcohol Dependence[J]. Acta Neuropharmacologica, 2013, 3(1): 23-27.
[1] World Health Organization. Global status report on alcohol and health[M]. Geneva, Switzerland: World Health Organization, 2011: 286. [2] 高丽波,钟树荣,包建军,等. 酒精依赖治疗的研究进展[J]. 医学研究杂志, 2010, 39(8): 107-110. [3] 梁建辉, 刘青. 酒精成瘾治疗药物药理活性筛选和药效学评价技术平台的研究[J]. 山西大同大学学报(自然科学版), 2009, 25(1):45-47. [4] David W Oslin, Wade H Berrettini, Charles P O’Brien. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone[J]. Addict Biol, 2006, 11(3-4):397–403. [5] Subhash C Pandey. The gene transcription factor cyclic AMP-responsive element binding protein: role in positive and negative affective states of alcohol addiction[J]. Pharmacol Ther, 2004, 104(1): 47-58. [6] George F Koob. Alcoholism: allostasis and beyond[J]. Alcohol Clin Exp Res, 2003, 27(2):232– 243. [7] George F Koob. Neuroadaptive mechanisms of addiction: studies on the extended amygdala[J]. Eur Neuropsychopharmacol, 2003, 13(6):442– 452. [8] Rueben A Gonzales, Martin O Job, William M Doyon. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement[J]. Pharmacol Ther, 2004, 103(2):121–146. [9] Subhash C Pandey, Navdha Mittal, Lawrence Lumeng, et al. Involvement of the cyclic AMP responsive element binding protein gene transcription factor in genetic preference for alcohol drinking behavior[J]. Alcohol Clin Exp Res, 1999, 23(9):1425-1434. [10] Subhash C Pandey, Zhang Huai-bo, Adip Roy, et al. Deficits in amygdaloid cAMP responsive element binding protein signaling play a role in genetic predisposition to anxiety and alcoholism[J]. J Clin Invest, 2005, 115(10):2762-2773. [11] Kevin P Conway, Wilson Compton, Frederick S Stinson, et al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions[J]. J Clin Psychiatry, 2006, 67(2):247–257. [12] 张振华, 邱毅, 赵振国, 等. 酒精成瘾的受体后信号转导[J]. 生理科学进展, 2008, 39(4): 319-324. [13] Subhash C Pandey, Toshikazu Saito, M Yoshimura, et al. cAMP signaling cascade:a promising role in ethanol tolerance and dependence[J]. Alcohol Clin Exp Res, 2001, 25(2):46S-48S. [14] Kaushik Misra, Subhash C Pandey. Differences in basal levels of CREB and NPY in nucleus accumbens regions between C57BL/6 and DBA/2 mice differing in inborn alcohol drinking behavior[J]. J Neurosci Res, 2003, 74(6):967-975. [15] Subhash C Pandey, Adip Roy, Zhang Huai-bo, et al. Partial deletion of the cAMP response element binding protein gene promotes alcohol drinking behaviors[J]. J Neurosci, 2004, 24(21):5022–5030. [16] Subhash C Pandey, Adip Roy, Zhang Huai-bo. The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats[J]. Alcohol Clin Exp Res, 2003, 27(3):396-409. [17] Andrew T Bender, Joseph A Beavo. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. Pharmacol Rev, 2006, 58(3):488–520. [18] Zhang Han-ting. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs[J]. Curr Pharm Des, 2009, 15(14):1688-1698. [19] S Perez-Torres, X Miro, J M Palacios, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: Comparison with monkey and rat brain[J]. J Chem Neuroanat, 2000, 20(3-4): 349–374. [20] Zhang Han-ting, Huang Ying, S-L Catherine Jin, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme[J]. Neuropsychopharmacology, 2002, 27(4): 587-595. [21] Li Yun-feng, Cheng Yu-fang, Huang Ying, et al. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling[J]. J Neurosci, 2011, 31(1):172–183. [22] Hu Wei, Tina Lu, Alan Chen, et al. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice[J]. Psychopharmacology, 2011, 218(2):331-339. [23] Wen Rui-ting, Zhang Min, Qin Wang-jun, et al. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring fawn-hooded rats[J]. Alcohol Clin Exp Res, 2012, 36(12):2157-2167. [24] Richard L Bell, Marcelo F Lopez, Cui Chang-hai, et al. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence [J]. Addict Biol, 2013, doi: 10.1111/adb.12106. [25] Mark A Giembycz, Stephen K Field. Roflumilast: first phosphodiesterase-4 inhibitor approved for treatment of COPD[J]. Drug Des Devel Ther, 2010, 21(4): 147-158. [26] Altana Roflumilast-APTA 2217, B9302-107, BY 217, BYK20869[J]. Drugs R D, 2004, 5(3): 176-181. [27] 李灵君, 韩尚河, 陈国良. 磷酸二酯酶-4抑制剂的研究进展[J]. 沈阳药科大学学报, 2013, 30(7):568-576. [28] Rajarshi Sengupta, Sun Tao, Nicole M Warrington, et al. Treating brain tumors with PDE4 inhibitors[J]. Trends Pharmacol Sci, 2011, 32(6):337-344. |
[1] | ZHANG Fang-fang1,ZHOU Yan-memg1,WANG Hao1,GAO Shan1,WANG Lei1,TAN Rui1,DU Xian1,ZHAO Xiao-min1,ZHANG Han-ting1,2 *.PDE4 Inhibitor Ameliorates Neuropathic Pain by Upregulating Spinal Connexin 43 Expression[J]. Acta Neuropharmacologica, 2018, 8(4): 8-9. |
[2] | WANG Hao1, ZHANG Fang-fang1, FU Hua-rong1, ZHOU Yan-meng1, LIU Xin1, HOU Xue-qin 1, HU Wei2, Rolf Hansen2, XU Ying3, James O’Donnell3, ZHANG Han-ting1,2.Targeting PDE4 for Alzheimer’s Disease and Alcoholism: An implication in Alcohol-Related Dementia?[J]. Acta Neuropharmacologica, 2018, 8(4): 39-41. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||